MPMimi R. Precit

Mimi R. Precit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mimi R. Precit has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Jennifer Dien Bard

    Department of Pathology and Laboratory Medicine, Children’s Hospital Los Angeles

    5 shared publications
  • Kanokporn Mongkolrattanothai

    Department of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California, USA

    3 shared publications
  • Utsav Pandey

    Department of Pathology and Laboratory Services, Westchester Medical Center/New York Medical College, Valhalla, NY

    3 shared publications
  • Rebecca Yee

    Department of Pathology and Laboratory Medicine, Children's Hospital of Los Angeles, Los Angeles, California, USA; Department of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC

    2 shared publications
  • Adam Waalkes

    University of Washington

    1 shared publication
  • Babak Moghimi

    Keck School of Medicine, University of Southern California, Los Angeles, USA

    1 shared publication

Latest Publications

  • Multiplex respiratory panel repeat testing in pediatric and young adult patients infrequently offers new clinical information

    by Mimi R. Precit, Utsav Pandey, Kanokporn Mongkolrattanothai, Rebecca Yee, Jennifer Dien Bard


  • Impact of FilmArray™ Respiratory Panel testing on the clinical management of pediatric bone marrow transplant patients

    by Mimi R. Precit, Kaidi He, Kanokporn Mongkolrattanothai, Babak Moghimi, Marisa Glucoft, Jennifer Dien Bard

    Viral respiratory tract infections cause significant morbidity in bone marrow transplant (BMT) patients. Speed and sensitivity of the FilmArray™ Respiratory Panel (FA-RP) can improve care but may prompt inappropriate testing. Studies describing FA-RP use in pediatric BMT patients are limited; we investigated FA-RP use, results, and clinical management to evaluate clinical significance of testing in pediatric BMT patients. Retrospective analysis of 671 respiratory specimens from 204 unique BMT patients between 01/01/2016 and 01/01/2019 was performed. Age, underlying diagnoses, FA-RP result, reason for FA-RP, and symptoms were abstracted. FA-RP impact on antimicrobial management, scheduled procedures, infection control measures, and hospital admission/discharge were investigated. Impacts of repeat testing were evaluated. Two hundred sixty-nine out of 671 specimens (40%) tested positive; human rhinovirus/enterovirus (hRV/hEV) was the most common (161/269, 60%). The primary reason for FA-RP was URI symptoms (402/671, 60%) with 54% testing positive. One hundred twenty-two out of 671 (18.2%) specimens were from asymptomatic patients; 14 (11.4%) tested positive. FA-RP informed antiviral initiation in 7/19 (36.8%), 7/8 (87.5%), and 5/30 (16.7%) of RSV, influenza, and human parainfluenza cases, respectively. In 11 cases, FA-RP informed azithromycin and ceftriaxone initiation, continuation, or discontinuation. BMT was delayed for three positives (two RSV, one hRV/hEV). In 22 instances, negative FA-RP cleared patients for BMT. In 70% of cases, repeats offered no new clinical information; all negative-to-positive cases had new or worsening respiratory symptoms. FA-RP was ordered on symptomatic and asymptomatic patients, provided rapid diagnosis in > 50% of symptomatic patients, and informed infection control measures for all inpatients and antiviral initiation in > 80% of influenza cases.


  • Open Access

    VP Shunt With Recurrent Malfunction in Two Pediatric Patients: Is the Hydrocephalus Truly Idiopathic?

    by Mimi R. Precit, Cynthia Enriquez, Michael Neely, Michael Smit, Jeffrey M. Bender, Jennifer Dien Bard, Vikram Anand, Sindhu Mohandas

  • Polyclonality, Shared Strains, and Convergent Evolution in Chronic Cystic Fibrosis Staphylococcus Aureus Airway Infection

    by Dustin R. Long, Daniel J. Wolter, Michael Lee, Mimi Precit, Kathryn McLean, Elizabeth Holmes, Kelsi Penewit, Adam Waalkes, Lucas R. Hoffman, Stephen J. Salipante

    Rationale: S. aureus is the most common respiratory pathogen isolated from patients with cystic fibrosis (CF) in the US. While modes of acquisition and genetic adaptation have been described for Pseudomonas aeruginosa, resulting in improved diagnosis and treatment, these features remain more poorly defined for S. aureus. Objectives: To characterize the molecular epidemiology and genetic adaptation of S. aureus during chronic CF airway infection and in response to antibiotic therapy. Methods: We performed whole genome sequencing of 1,382 S. aureus isolates collected longitudinally over a mean 2.2 years from 246 children with CF at five US centers between 2008-2017. Results were integrated with clinical and demographic data to characterize bacterial population dynamics and identify common genetic targets of in vivo adaptation. Measurements and Main Results: 45.5% of patients carried multiple, coexisting S. aureus lineages, often having different antibiotic susceptibility profiles. Adaptation during the course of infection commonly occurred in a set of genes related to persistence and antimicrobial resistance. Individual sequence types demonstrated wide geographic distribution, and we identified limited strain sharing among children linked by common household or clinical exposures. Unlike P. aeruginosa, S. aureus genetic diversity was unconstrained, with ongoing flow of new genetic elements into the population of isolates from children with CF. Conclusions: CF airways are frequently co-infected by multiple, genetically distinct S. aureus lineages, indicating that current clinical procedures for sampling isolates and selecting antibiotics are likely inadequate. Strains can be shared by patients in close domestic or clinical contact and undergo convergent evolution in key persistence and antimicrobial resistance genes, suggesting novel diagnostic and therapeutic approaches for future study.


  • Statewide surveillance of carbapenemase-producing carbapenem-resistant Escherichia coli and Klebsiella species in Washington state, October 2012-December 2017

    by Mimi R. Precit, Kelly Kauber, William A. Glover, Scott J. Weissman, Tashina Robinson, Michael Tran, Marisa D’angeli

    Background: Carbapenem-resistant Enterobacterales (CRE) are common causes of healthcare-associated infections and are often multidrug resistant with limited therapeutic options. Additionally, CRE can spread within and between healthcare facilities, amplifying potential harms. Objective: To better understand the burden, risk factors, and source of acquisition of carbapenemase genes in clinical Escherichia coli and Klebsiella spp isolates from patients in Washington to guide prevention efforts. Design: Multicenter prospective surveillance study. Methods: Escherichia coli and Klebsiella spp isolates meeting the Washington state CRE surveillance case definition were solicited from clinical laboratories and tested at Washington Public Health Laboratories using polymerase chain reaction (PCR) for the 5 most common carbapenemase genes: bla(KPC), bla(NDM), bla(IMP), bla(VIM), and bla(OXA-48). Case patients positive by PCR were investigated by the public health department. Results: From October 2012 through December 2017, 363 carbapenem-resistant E. coli and Klebsiella spp isolates were tested. Overall, 45 of 115 carbapenem-resistant K. pneumoniae (39%), 1 of 8 K. oxytoca (12.5%), and 28 of 239 carbapenem-resistant E. coli (11.7%) were carbapenemase positive. Of 74 carbapenemase-positive isolates, bla(KPC) was most common (47%), followed by bla(NDM) (30%), bla(OXA-48) (22%), and bla(IMP) (1%). Although all cases had healthcare exposure, bla(KPC) acquisition was associated with US health care, whereas non-bla(KPC) acquisition was associated with international health care or travel. Conclusions: We report that bla(KPC), the most prevalent carbapenemase in the United States, accounts for nearly half of carbapenemase cases in Washington state and that most KPC-cases are likely acquired through in-state health care.


  • Open Access

    A Case Report of Neonatal Acute Respiratory Failure Due to Severe Acute Respiratory Syndrome Coronavirus-2

    by Mimi R Precit, Rebecca Yee, Vikram Anand, Kanokporn Mongkolrattanothai, Utsav Pandey, Jennifer Dien Bard


  • Cerebrospinal Fluid Findings Are Poor Predictors of Appropriate FilmArray Meningitis/Encephalitis Panel Utilization in Pediatric Patients

    by Mimi R. Precit, Rebecca Yee, Utsav Pandey, Margil Fahit, Cheryl Pool, Samia N. Naccache, Jennifer Dien Bard

    Molecular testing of cerebrospinal fluid (CSF) using the BioFire FilmArray meningitis/encephalitis (FA-M/E) panel permits rapid, simultaneous pathogen detection. Due to the broad spectrum of targeted organisms, FA-M/E testing may be restricted to patients with abnormal CSF findings. We sought to determine if restriction is appropriate in our previously healthy and/or immunocompromised pediatric patients. FA-M/E was ordered on 1,025 CSF samples from 948 patients; 121 (11.8%) specimens were FA-M/E positive. Of these, 89 (73.6%) were virus positive, and 30 (24.8%) were bacterium positive. The most common targets detected were enterovirus (n = 38), human herpesvirus 6 (HHV-6) (n = 30), and Streptococcus pneumoniae (n = 14). Pleocytosis with white blood cell (WBC) levels of ≥5 cells/mm3 and ≥10 cells/mm3 were found in 33.1% and 24.3% of all specimens, respectively. Using WBC levels of ≥5 cells/mm3, 63.4% (59/93) of positive specimens exhibited pleocytosis, compared to 29.5% (233/789) of negative specimens. Among positive specimens, 54.4% (37/68) of viral and 87% (20/23) of bacterial cases had pleocytosis. The use of a pleocytosis cutoff of ≥10 cells/mm3 would have missed an additional enterovirus, one cytomegalovirus (CMV), and two HHV-6 diagnoses. CSF glucose and protein levels were normal for 83/116 (75.2%) and 51/116 (44%) positive specimens. Abnormal glucose in combination with WBC levels of ≥10 cells/mm3 showed high specificity (94.5%) and was a better predictor of FA-M/E positivity than abnormal protein. Sensitivity and positive predictive values were <90% for all biomarkers. CSF pleocytosis and abnormal glucose/protein were poor predictors of FA-M/E. Restricting FA-M/E orders based on pleocytosis or other abnormal parameters would have resulted in missed diagnostic opportunities, particularly for the detection of viruses in both previously healthy and immunocompromised patients.